This week's episode covers a multistate rise in cyclosporiasis infections, insights from a Yale psychiatrist on safety monitoring for psychedelic therapies, and a wave of FDA approvals spanning nephrology, gene therapy, and cell therapy—plus a major expansion of the NIH's All of Us Research Program.
Kasey Malotte, PharmD, BCPS, discusses the new credential’s strengths and areas for growth as well as why a stronger training ecosystem is necessary for long-term impact.
Utah's AI-powered prescription refill pilot is fueling debate over how artificial intelligence can improve medication access and workflow efficiency while preserving the clinical oversight needed to ensure patient safety.
A study finds low-income and minority families are likely among those experiencing consequences from reduced measles, mumps, rubella, and varicella (MMRV) vaccine uptake amid the worst surge in US measles cases in decades.
The FDA approval gives patients with multiple myeloma a second subcutaneous anti-CD38 option alongside daratumumab.
Pharmacy Times interviews Nicole McMullen, PharmD, regional clinical pharmacist at American Oncology Network, on patient and caregiver education, home monitoring, multidisciplinary coordination, and key lessons for community oncology practices implementing outpatient BiTE therapy.
The FDA expanded Wilate's approval for routine prophylaxis to reduce bleeding episodes in children younger than 6 years with von Willebrand disease, supported by phase 3 WIL-33 data showing low annualized bleeding rates and favorable tolerability.
A study published in JAMA Network Open of opioid-naive patients with acute pain found that opioids were typically used in low doses and for short periods, but pain often lasted longer than expected, and leftover medication was common.
Ennumo is approved for the same indications as its reference product, Neulasta (pegfilgrastim).
These recommendations for acute pulmonary embolism management are most applicable to pharmacists on the interdisciplinary team managing acute PE.
In an interview with Pharmacy Times, Deanna Horner, PharmD, BCPS, discusses how pharmacists can serve as patient advocates in GLP-1 care and how direct access models may simplify the patient journey while preserving clinical oversight.
Tanya J. Uritsky, PharmD, BCPP, FPPCP, FASHP, discusses multimodal analgesia, acute pain pathways, opioid-tolerant patients, suzetrigine, and pharmacist-led interventions across health systems with Pharmacy Times.
A preclinical study demonstrates protective immunity against flu, COVID-19, and RSV without immune interference.
New findings show chronic kidney disease affects the same share of US adults as in 2013, although the disease is increasingly tied to diabetes and heart conditions.
Advances in antibiotic and microbiome-based therapies may reduce recurrence and improve outcomes in patients with recurrent Clostridioides difficile infection.
The authors said these data support the safety of current coadministration practice.
Pharmacy Times interviews Nicole McMullin, regional clinical pharmacist at American Oncology Network, about the oncology pharmacist’s role in outpatient BiTE therapy and the monitoring protocols for identifying and managing CRS and ICANS during step-up dosing.
Danish study links meningioma risk to progestogen contraceptives, including injectable depot medroxyprogesterone acetate and levonorgestrel intrauterine devices.
In an interview with Pharmacy Times, Deanna Horner, PharmD, BCPS, discusses how data, automation, provider-led programs, and pharmacist support can help improve GLP-1 access, appropriate use, adherence, and patient persistence.
In an interview with Pharmacy Times, Matt Christian, director of Supply Chain Insights at USP, discussed the factors driving long-term shortages, the growing role of geographic concentration, and what pharmacists should understand about supply chain resilience.
In addition to the upcoming Annual Forum in September, New England Institute of Ambulatory Care Pharmacists (NEIAP) provides practical education and networking opportunities to support ambulatory care pharmacists.
Katelyn O'Brien, PharmD, BCPS, CDCES, BC-ADM, discusses the New England Institute of Ambulatory Care Pharmacists (NEIAP) Annual Forum and previews key topics of discussion.
As cannabis evolves, pharmacists must recognize emerging risks from high-potency products, drug interactions, and use-related syndromes to improve patient safety.
Laura Gillespie, PharmD, discusses how her patient-first approach has guided her research collaboration efforts and led to measurable reductions in C difficile infection rates at her institution.
Deanna Horner, PharmD, BCPS, discusses how payers, employers, and health plans can approach GLP-1 coverage by balancing patient access, affordability, clinical value, and long-term cost considerations.
Jennifer Goldman, PharmD, RPh, CDCES, BC-ADM, FCCP, shares the history and mission of NEIAP and explains how the organization provides practical education and networking opportunities.
In addition to explaining how NEIAP has evolved over time, Katelyn O'Brien, PharmD, BCPS, CDCES, BC-ADM, previews key topics at the upcoming September meeting.
Peer Reviewed
This study validates the need for universal HBV therapy for hepatitis B infections among people coinfected with HIV.
The FDA expanded Casgevy’s indication to include children 2 years and older with sickle cell disease with recurrent VOCs or transfusion-dependent β-thalassemia, making it the first gene therapy approved for patients as young as 2 years with SCD.
By targeting aldosterone synthesis directly, baxdrostat offers a novel mechanism for addressing resistant hypertension.
